ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Herpes ZosterShingles
Interventions
BIOLOGICAL

Zoster Vaccine Live

Zoster vaccine live

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01556451 - ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) | Biotech Hunter | Biotech Hunter